amgen’s approah to “value ased healthare” in … riband vp international policy &...
TRANSCRIPT
HERB RIBANDVP INTERNATIONAL POLICY & GOVERNMENT AFFAIRS16 OCTOBER 2017
AMGEN’S APPROACH TO “VALUE-BASED HEALTHCARE” IN EUROPE
Amgen Proprietary - For Internal Use Only
2
TODAY’S DISCUSSION FOCUSES ON THREE TOPICS
1. Mounting healthcare system pressures in Europe require new approaches to innovation and healthcare delivery
2. Europe can ensure sustainable, high quality healthcare systems by improving value (“value = improved patient outcomes / total cost”)
3. To achieve this we need to build win-win partnerships to measure and improve outcomes and recalibrate the policy environment
Amgen Proprietary - For Internal Use Only
3
AGEING EUROPEAN POPULATIONS FACE A COSTLY AND GROWING BURDEN OF SERIOUS DISEASE…
Source: EFPIA “Healthier future” (2016), citing BCG analysis of OECD and WHO data (2014)
… But today live with unacceptably high variations in health outcomes
• 9x variation in radical prostatectomy complication rates within a country
• 7x variation in breast cancer re-operation rates within a country
• 4x variation in lung cancer 5-year survival across OECD countries
Reasons: Focus on inputs (only), data fragmentation, clinical practice/care pathway variations, transaction-based incentives, different HTA/purchasing/cost containment mechanisms, etc.
Health systems need to reduce inefficiencies and drive
improved outcomes in relation to all 100% of HC budgets
Amgen Proprietary - For Internal Use Only
4
WE NEED TO REORIENT THE THINKING IN EUROPE ABOUT SUSTAINABLE HEALTHCARE SYSTEMS
From (today’s focus):
Managing Cost
To:
Enhancing Value
• Innovation “not affordable”
• Focus on short-term budget impact
• Systems measure inputs (spending, silo’d budgets)
• Disregard for quality & outcomes variations
• Innovation that enhances quality and efficiency
• Value to patients and society
• Systems measure and improve outcomes in relation to total cost
• Holistic approaches to reduce variations and improve outcomes
Amgen Proprietary - For Internal Use Only
5
1. See the work of Porter et al: http://www.isc.hbs.edu/health-care/vbhcd/pages/default.aspx
2. Quality of life, improved productivity, cost avoidance, etc.
WE CAN ENHANCE VALUE BY IMPROVING PATIENT OUTCOMES RELATIVE TO TOTAL COST
Cost of delivering the outcomes
Patient-relevant health outcomes achievedVALUE
1
=
Starting point:
Define, enhance and
measure patient-
relevant outcomes
Better quality care can
be less expensive
over the long-term
Better quality care at
equal or lower cost
leads to higher value
for the system
Improve outcomes
Reduce overall costs
Increase value
Value-based healthcare: Delivering highest value from a healthcare system
point of view by focusing on best patient–relevant outcomes/benefits2 in
relation to total cost to the healthcare system.
Amgen Proprietary - For Internal Use Only
6
ENHANCING VALUE BRINGS BENEFITS FOR PATIENTS, HEALTHCARE SYSTEMS AND SOCIETY
Health Status
Process
Sustainability
Survival
Degree of health or recovery
Sustainability of health and avoidance of recurrences
Reduced complications from therapy (e.g., care-induced illnesses)
Time to recovery / return to normal activities
Efficiency of care / treatment pathways (e.g., diagnostic errors, complications, ineffective care, waste)
Amgen Proprietary - For Internal Use Only
7
AMGEN AIMS TO PROVIDE INNOVATIVE VALUE-BASED HEALTHCARE SOLUTIONS…
to help ensure that all appropriate patients benefit from our medicines…
that are truly patient-centric and valuable in the real world…
that are integrated across the patient care pathway, personalized to patient conditions,
circumstances and tailored to their preferences…
and maximize quality and efficiency, proven through real-world evidence.
Amgen Proprietary - For Internal Use Only
8
AMGEN IS DEVELOPING NEW APPROACHES TO ADDRESS DISEASES WITH HIGH UNMET NEEDS
High Risk CV • Multiple Myeloma/ Oncology • OsteoporosisDiseases
Areas for
Innovation ClinicalDevelopment
Patient ID &Diagnosis
Patient Support & Adherence
RWD Capabilities & Analytics
Role of technology and
data
• FH Patient ID
• EMR Integration
• Milestone mapping
• EHR decision support
• Predictive analytics
• Adherence solutions
• Bluetooth monitoring
• Sensors and devices
• Connected health
• Tailoring tech to homecare
• RWD partnerships
• RWD science
• Emerging analytics technology
• Clinical trial recruitment
• PV and safety
• New clinical end points
• Digital biomarkers
• Genomic data mining and R&D
Examples
Amgen Proprietary - For Internal Use Only
9
AMGEN IS LAUNCHING “VBHC” PROGRAMS IN TEN EUROPEAN COUNTRIES
High risk CVD patient identification; adherenceMultiple myeloma patient care pathway
Cancer/bone mets care pathway Osteoporosis patient identification; adherence
Amgen Proprietary - For Internal Use Only
10
CASE STUDY (UK): IMPROVING THE CARE PATHWAY FOR CANCER PATIENTS WITH BONE METASTESES
Mrs. FB, native of Liverpool; 46 years old
• Small business owner, wife and mother
• Diagnosed with metastatic breast cancer
Clatterbridge Cancer Centre NHS Foundation
• One of UK’s largest cancer networks
• Serving 2.3 million people
Amgen Proprietary - For Internal Use Only
11
• Travelling ~2 hours to hospital
• Personal / travel costs ~£200/mo.
• Inferior IV therapies at hospital
• Chemo unit and beds at capacity
• National targets at risk (££ fines)
• Hospital costs 8-10X higher
PREVIOUSLY THE SITUATION WAS SUBOPTIMAL FOR ALL STAKEHOLDERS
• NHS “QIPP” program (2012--)
• Seeking ~£20 billion in savings
• Difficult to achieve!
PATIENT HOSPITAL NHS
Amgen Proprietary - For Internal Use Only
12
A REDESIGNED, PATIENT-CENTRIC SERVICE AIMED FOR “BETTER CARE, CLOSER TO HOME”
• Patient choice: hospital, local clinic or home injection via
mobile nurses
• Hospital efficiency: outpatient pharmacy to supply drugs
for home administration; reinvest cost savings in
innovation
• Safety first: focus on patient safety-health with ongoing
physician/nurse guidance
• Integrated approach: clinical governance and protocols
for check-ups, tests, etc.
Amgen Proprietary - For Internal Use Only
13
• Cancer and bone complications
under control
• Best therapy, convenient setting
• Saving time and ££ each month
• Freed-up capacity to treat
patients per national guidelines
• Reinvesting cost savings
• 100% patient satisfaction!
TODAY THE SITUATION IS DRAMATICALLY IMPROVED FOR ALL CONCERNED
• Proof: QIPP can work well
• Lower overall costs
• 100% patient (voter) satisfaction!
PATIENT WIN !! HOSPITAL WIN !! NHS WIN !!
Amgen Proprietary - For Internal Use Only
14
• Clatterbridge/Amgen partnership
recognized as best practice
• 2015 National Pharmacy Mgmt. Forum
(NHS payer conference) award:
“Best Industry/NHS Partnership” --
Dept. of Health, NHS England now
working to replicate this program
• 2016 EU “Health Collaboration Award”
THE VALUE OF THIS PARTNERSHIP HAS BEEN RECOGNIZED AT UK AND EU LEVELS
Amgen Proprietary - For Internal Use Only
15
TO BE SUCCESSFUL WITH VBHC, WE NEED ALL HEALTHSYSTEM STAKEHOLDERS TO ENGAGE AND COMMIT
Payers:
Evidence-based
reimbursement;
pay for outcomes
Policymakers:
Outcomes-based
HC systems
Providers:
Evidence-based
medicine
Patients:
Agree to share
data
Commit to
a new
approach
Demonstrate value
Focus on patient
outcomes
Proactively engage
stakeholders
Optimize the product
life-cycle
Industry
€
Amgen Proprietary - For Internal Use Only
THANK YOU
Amgen Proprietary - For Internal Use Only